drugset / Trial / NCT07218809
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Phase 3
Recruiting
1100 enrolled
AstraZeneca
European Network of Gynaecological Oncological Trial Groups (ENGOT) · collabGOG Foundation · collabVentana Medical Systems, Inc · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.
Timeline
- Start
- 2025-12-29
- Primary completion
- 2028-11-17
- Completion
- 2030-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD5335 | Unknown | — | Intravenous |
| Comparator | Doxorubicin | Other / unclassified | — | Intravenous |
| Comparator | Mirvetuximab Soravtansine | Other / unclassified | — | Intravenous |
| Comparator | Paclitaxel | Small molecule | — | Intravenous |
| Comparator | Topotecan | Small molecule | — | Intravenous |